Immediate Impact
18 standout
Citing Papers
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
Translating p53-based therapies for cancer into the clinic
2024 Standout
Works of Vojtěch Bystrý being referenced
Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Vojtěch Bystrý | 90 | 78 | 130 | 82 | 23 | 261 | |
| Hussein Ghamlouch | 152 | 129 | 109 | 85 | 25 | 327 | |
| G. García-Manero | 106 | 104 | 159 | 79 | 22 | 315 | |
| Fransien de Boer | 89 | 114 | 126 | 35 | 14 | 315 | |
| Alexandra Oltová | 107 | 35 | 143 | 86 | 19 | 255 | |
| Maria Regina Régis Silva | 90 | 48 | 58 | 48 | 30 | 256 | |
| Annamaria Giordano | 67 | 34 | 49 | 71 | 14 | 240 | |
| D Falzetti | 110 | 29 | 85 | 75 | 19 | 292 | |
| Nayera Hamdy | 135 | 44 | 91 | 52 | 24 | 311 | |
| Adam Krejčí | 73 | 55 | 56 | 55 | 15 | 195 | |
| Ana Inés Landoni | 189 | 122 | 128 | 77 | 17 | 324 |
All Works
Login with ORCID to disown or claim papers
Loading papers...